Deerfield Management Portfolio
13F Holdings & Position Changes — Last filed Aug 14, 2026
13F Holdings & Position Changes — Last filed Aug 14, 2026
Multi-strategy healthcare fund with one of the longest track records in the space. Deerfield invests across public equity, private equity, structured credit, and royalties in healthcare. Known for creative financing structures and deep industry relationships across pharma and biotech.
Deerfield Management is a $16B biotech-focused hedge fund managed by James Flynn. As of their latest 13F filing (Q2 2026), the fund holds 63 positions worth $7.3B. This quarter they initiated 6 new positions and exited 613. Their largest holding is NUVL ($2.1B).
Deerfield initiated 6 new positions and increased 15 this quarter. Portfolio grew +168.3% to $7.3B. 1000 upcoming catalysts across holdings.
Portfolio Value (13F)
$7.3B
Holdings
63
Top 10 Concentration
60.2%
QoQ Change
+168.3%
Turnover
1.8%
Portfolio Value Trend
Be first to know when Deerfield Management files next quarter
Get an email the moment new buys, exits, and conviction changes hit. Free 14-day trial.
| # | Ticker | Company | Change | Value | % of Portfolio | SI % Float ? | Trend |
|---|---|---|---|---|---|---|---|
| 1 | NUVL | Nuvalent Inc. | $2.1B | 29.06% | — | — | |
| 2 | RVMD | Revolution Medicines Inc. | Increased | $448.0M | 6.11% | 4.8% | |
| 3 | PRAX | Praxis Precision Medicines, Inc. | $322.5M | 4.40% | 13.3% | — | |
| 4 | VTRS | Viatris Inc. | $320.9M | 4.38% | 3.2% | ||
| 5 | UTHR | United Therapeutics Corporation | $247.6M | 3.38% | — | — | |
| 6 | LEGN | Legend Biotech Corporation | Increased | $235.0M | 3.21% | 21.9% | — |
| 7 | COGT | Cogent Biosciences Inc. | Decreased | $193.7M | 2.64% | 10.7% | |
| 8 | GNMSF | Genmab A/S | Increased | $188.6M | 2.57% | — | — |
| 9 | VERA | Vera Therapeutics Inc. | Increased | $168.1M | 2.29% | 26.6% | |
| 10 | IONS | Ionis Pharmaceuticals Inc. | $157.0M | 2.14% | 16.7% | — |
Share changes reflect active decisions. Value changes include price moves.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
See all 63 holdings (you're viewing the top 10), plus 2 quarters of position history.
No charge for 14 days · Cancel anytime
Deerfield Management held 63 biotech stocks in their 13F portfolio this quarter. Their top positions include NUVL, RVMD, PRAX, VTRS, UTHR. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Deerfield Management's tracked biotech portfolio is worth $7.3B across 63 positions, with total assets under management of approximately $16B. Portfolio values are based on 13F filings with the SEC.
Deerfield Management initiated 6 new positions this quarter, including PBLS, AVLN, ODTX, ALMR, ADAG and 1 more. They also increased 15 existing positions.
Deerfield Management fully exited 613 positions this quarter, including FAST, THRM, TFX, SNX, REPL and 608 more. They also trimmed 10 existing positions.
Multi-strategy healthcare fund with one of the longest track records in the space. Deerfield invests across public equity, private equity, structured credit, and royalties in healthcare. Known for creative financing structures and deep industry relationships across pharma and biotech.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free Trial